[1-3]-beta-D-glucan - a new marker for the early serodiagnosis of deep-seated fungal infections in humans

• Autorzy: Kedzierska A
• Języki publikacji: EN

Abstrakty

EN

Until recently, the diagnosis of systemic mycoses was mainly based on traditional methods producing late and inconclusive results. Currently used methods of serological diagnostics are generally based on detection of cell wall components of selected pathogenic fungal species - mannoproteins, functioning as a antigenic markets. There are big hopes for adaptation of commercially available assays to detect (1—>3)-β-D-glucan because of the fact that its presence in blood and normally sterile body fluids should lead to initiation of the diagnostic workup of invasive fungal infection. Monitoring (1—>3)-β-D-glucan antigenemia is useful in predicting the therapeutic outcome of patients with invasive aspergillosis and in combination with galactomannan detection to identify false-positive reactions. The simultaneous use of both tests is probably more pertinent for the differentiation between yeast and mould infections.

Słowa kluczowe

EN

cell wall component; [1-3]-beta-D-glucan; systemic candidiasis; man; new marker; antigenic marker; diagnostic method; early serodiagnosis; fungal infection; invasive aspergillosis

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2007
• Tom: 56
• Numer: 1
• Opis fizyczny: p.3-9,ref.

Twórcy

autor

Kedzierska A

• Jagiellonian University Medical College, Wielicka 265, 30-663 Krakow, Poland

Bibliografia

• Aibiki M., Ohtsubo, S. Nishiyama, T. Oka, H. Dote and Y. Shirakawa. 2005. Elevated serum (1—>3)-ß-D-glucan level and depressed neutrophil phagocytosis in a heatstroke patient. Resuscitation 65: 115-117.
• Battle J., T. Ha, C. Li, V. Delia Beffa, P. Rice, J. Kalbfleisch, W. Browder and D. Williams. 1998. Ligand binding to the (1—>3)-ß-D-glucan receptor stimulates NFkB activation, but not apoptosis in U937 cells. Biochem. Biophys. Res. Commun. 249: 499-504.
• Cheung N-K.V., S. Modak, A. Vickers and B. Knuckles. 2002. Orally administered ß-glucans enhance anti-tumour effects of monoclonal antibodies. Cancer Immunol. Immunother. 51: 557-564.
• Digby J., J. Kalbfleisch, A. Glenn, A. Larsen, W. Browder and D. Williams. 2003. Serum glucan are not specific for presence of fungal infections in intensive care unit patients. Clin. Diagn. Lab. Immunol. 10: 882-885.
• Engstad C.S., R.E. Engstad, J.O. Olsen and B. Ostcrud. 2002. The effect of soluble beta-1, 3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood. Int. Immunopharmacol. 2: 1585-1597.
• Gonzalez J.A., J.D. Digby, P.J. Rice, K.F. Brcuel, W.K. DePonti, J.H. Kalbfleisch, I.W. Browder and D.L. Williams. 2004. At low serum glucan concentrations there is an inverse correlation between serum glucan and serum cytokine levels in ICU patients with infections. Int. Immunopharmacol. 4: 1107-1115.
• Hong E, R.D. Hansen, J. Yan, D.J. Allendorf, J.T. Baran, G.R. Ostroff and G.D. Ross. 2003. β-glucan as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63: 9023-9031.
• Horvath J. A. and S. Dummer. 1996. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am. J. Med. 100: 171-178.
• Hossain M.A., T. Miyazaki, K. Mitsutakc, H. Kakcya, Y. Yamamoto, K. Yanagihara, S. Kawamura, T. Otsubo, Y. Hirakata, T. Tashiro and S. Kohno. 1997. Comparison between Wako-WB003 and Fungitec G tests for detection of (1—>3)-β-D-glucan in systemic mycosis. J. Clin. Lab. Anal. 11: 13-11.
• Imai K., Ashitani, J. Imazu, Y. Yanagi, S. Sano, A. Tokojima and M. Nakazato. 2004. Farmer's lung cases of a farmer and his son with high BAL fluid P-D glucan levels (in Japanese). Nihon Kokyuki Gakkai Zasshi. 42: 1024-1029.
• Ishizuka Y., H. Tsukada and F. Gejyo. 2004. Interference of (1—>3)-β-D-glucan administration in the measurement of plasma (1—>3)-β-D-glucan. Int. Med. 43: 97-101.
• Kami M., Y. Tanaka, Y. Kanda, S. Ogawa, T. Masumoto, K. Ohtomo, T. Matsumura, T. Saito, U. Machina and T. Kashima. 2000. Computed tomographic scan of the chest, latex agglutination test and plasma (1 —>3)-β-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: A prospective study of 215 patients. Haematologica 85: 745-752.
• Kanda H., K. Kubo, K. Hamasaki, Y. Kanda, A. Nakao, T. Kitamura, T.Fujita, K. Yamamoto and T. Mimura. 2001. Influence of various hemodialysis membranes on the plasma (1—>3)-β-D-glucan level. Kidney Int. 60: 319-323.
• Kawai R., K. Igarashi, M. Yoshida, M. Kitaoka and M. Samejima. 2005. Hydrolysis of P-l,3/l,6-glucan by glycoside hydrolase family 16 endo-l,3(4)-β-glucanase from the basidiomy-cete Phanerochaete chrysosporium. Appl. Microbiol. Biotechnol: X 1-9 (Epub ahead of print).
• Kondori N., L. Edebo and L Mattsby-Baltzer. 2004. Circulating P (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin. Diagn. Lab. Immun. 11: 344-350.
• Kougias P., D. Wei, P.J. Rice, H.E. Ensley, J. Kalbfleisch, D.L. Williams and W. Browder. 2001. Normal human fibroblasts express pattern recognition receptors for fungal (1—>3)-D-glucans. Infect. Immun. 69: 3933-3938.
• Maertens J., J. Verhaegen, K. Lagrou, J. Van Elderle and M. Boogaerts. 2001. Screening for circulating galactomannan as a non-invasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and steam cell transplantation recipients: a prospective validation. Blood 97: 1604-1610.
• Martino R. and M. Subira. 2002. Invasive fungal infection in haematology: new trends. Ann. Hematol. 81: 233-243.
• Miura N.N., Y. Adachi, T. Yadomac, H. Tamura, S. Tanaka and N. Ohno. 2003. Structure and biological activities of β-glucans from yeast and mycelial forms of Candida albicans. Microbiol. Immunol. 47: 173-182.
• Miyazaki T., S. Kohno, K. Mitsutake, S. Maesaki, K. Tanaka, N. Ishikawa and K. Hara. 1995. Plasma (1—>3)-β-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis. J. Clin. Microbiol. 33: 3115-3118.
• Mueller A., J. Raptis, P.J. Rice, J.H. Kalbfleisch, R.D. Stout, H.E. Ensley, W. Browder and D.L. Williams. 2000. The influence of glucan polymer structure and solution conformation on binding to (1—>3)-ß-D-glucan receptors in a human monocytes-like cell line. Gfycobiology 10: 339-346. Mueller A., P.J. Rice, H.E. Ensley, P.S. Coogan, J.H. Kalbfleisch, J.L. Kelley, E.J. Love, CA. Portera, T. Ha, I.W. Browder and D.L. Williams. 1996. Receptor binding and internalization of water-soluble (1 —>3)-ß-D-glucan biologic response modifier in two monocytes/macrophage cell lines. J. Immunol. 156: 3418-3425.
• Nagasawa K., T. Yano, G. Kitabayashi, H. Morimoto, Y. Yamada, A. Ohata, M. Usami, T. Horiuchi and D. Eng. 2003. Experimental proof of contamination of blood components by (1 —>3)-ß-D-glucan caused by filtration with cellulose filters in the manufacturing process. J. Artif. Organs 6: 49-54.
• Nakao A., M. Yasui, T. Kawagoc, H. Tamura, S. Tanaka and H. Takagi. 1997. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular cafcinoma with cirrhosis. Hepatogastroenterology 44: 1413-1418.
• Obayashi T., M. Yoshida, T. Mori, H. Goto, A. Yasuoka, H. Iwasaki, H. Teshima, S. Kohno, A. Horiuchi and A. Ito. 1995. Plasma (1 —>3)-ß-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345: 17-20.
• Odabasi Z., G. Mattiuzzi, E. Estey, H. Kantarjian, F. Saeki, R.J. Ridge, P.A. Ketchum, M.A. Finkelman, J.H. Rex and L. Ostrosky-Zeichner. 2004. ß-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clin. Infect. Dis. 39: 199-205.
• Ostrosky-Zeichner L., B.D. Alexander, D.H. Kett, J. Vazquez, P.G. Pappas, F. Saeki, P.A. Ketchum, J. Wingard. R. Schiff, H. Tamura, M.A. et al. 2005. Multicenter clinical evaluation of (1—>3)-ß-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41: 654-659.
• Pazos C, J. Ponton and A. Del Palacio. 2005. Contribution of (1 —>3 )-ß-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galacto-mannan. J. Clin. Micmbiol. 43: 299-305.
• Reichenberger F., J.M. Habicht, A. Gratwohl and M. Tamm. 2002. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur. Respir. J. 19: 743-755.
• Ruhnke M., A. Böhme, D. Buchheidt, K. Donhuijsen, H. Einsele, R. Enzensberger, A. Glasmacher, H. Gumbel, CP. Heussel, M. Karthus et al. 2003. Diagnosis of invasive fungal infections in haematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann. Hematol. 82(Suppl 2): 141-148
• Sendid B., M. Tabouret, J.L. Poirot, D. Mathieu, J. Fruit and D. Poulain. 1999. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis.J. Clin. Microbiol. 37: 1510-1517.
• Takebayashi H., A. Mizota and M. Tanaka. 2005. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefes Arch. Clin. Exp. Ophthalmol. 6 1-5.
• Takesue Y. 2004. Strategy for the treatment of fungal infections in critically ill surgical patients. Nippon Ishinkin Gakkai Zasshi (in Japanese). 45: 217-221.
• Uchiyama M., N. Ohno, N.N. Miura, Y. Adachi, M.W. Aizawa, H. Tamura, S. Tanaka and T. Yadomae. 1999. Chemical and immunochemical characterization of limulus factor G-activating substance of Candida spp. FEMS Immunol. Med. Microbiol. 4: 411-420.
• Upton A., W. Leiscnring and K.A. Marr. 2006. (13) β-D-glucan assay in the diagnosis of invasive fungal infections. Clin. Infect. Dis. 42: 1054-1056.
• Usami M., A. Ohata, T. Horiuchi, K. Nagasawa, T. Waka-bayashi and S. Tanaka. 2002. Positive (1—>3)-β-D-glucan in blood components and release of (1—>3) β-D-glucan from depth-type membrane filters for blood processing. Transfusion 42: 1189-1195.
• Vassallo R. 1999. Fungal β-glucan can yield false-positive results with the Limulus Amebocyte Lysate Endotoxin Assay. Chest 116: 583-584.
• Verweij P.E. and J.F. Meis. 2000. Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl. Infect. Dis. 2: 80-87.
• Vetvicka V., B.P. Thornton and G.D. Ross. 1996. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating ofiC3b-opsonozed target celis. J. Clin. Invest. 98: 50-61.
• Willment J.A., S. Gordon and G.D. Brown. 2001. Characterization of the human β-glucan receptor and its alternatively spliced isoforms. J. Biol. Chem. 276: 43818-43824.
• Wingard J.R. and H.A. Leather. 2004. New era of antifungal therapy. Biol. Blood Marrow Transplant. 10: 73-90.
• Yasuoka A., N. Tachikawa, K. Shimada, S. Kiura and S. Oka. 1996. (1—>3)-β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin. Diagn. Lab. Immunol. 3: 197-199.
• Yeo S.F. and B. Wong. 2002. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin. Microbiol. Rev. 15: 465-484.
• Yoshida M., T. Obayashi, A. Iwama, M. Ito, S. Tsunoda, T. Suzuki, K. Muroi, M. Ohta, S. Sakamoto and Y. Miura. 1997. Detection of plasma (1-3)-β-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces, and Acremonium fungaemias. J. Med. Vet. Mycol. 35: 371-374.
• Yuasa K., H. Goto, M. Iguchi, T. Okamura and R. Ieki. 1996. Evaluation of the diagnostic value of the measurement of (1 —>3)-β-D-glucan in patients with pulmonary aspergillosis. Respiration 63: 78-83.